<p>马里兰州退休与养老金系统在第一季度减少了对艾伯维公司（NYSE:ABBV - 免费报告）13.2% 的持股，具体信息见其最近向 SEC 提交的 13F 表格。该基金在此期间出售了 12,656 股后，持有 82,955 股该公司的股票。根据其最近的 SEC 文件，马里兰州退休与养老金系统在艾伯维的持股价值为 17,381,000 美元。</p>
<ul>
<li>艾伯维股票关注突破，管道和利润增长</li>
</ul>
<p>其他对冲基金也对该公司的持股进行了增减。GAMMA Investing LLC 在第一季度将其在艾伯维的持股增加了 25,841.6%。GAMMA Investing LLC 目前拥有 10,234,737 股该公司的股票，价值 2,144,382,000 美元，此前在上个季度又购买了 10,195,284 股。高盛集团在第一季度将其在艾伯维的持股增加了 31.6%。高盛集团目前拥有 14,646,908 股该公司的股票，价值 3,068,820,000 美元，此前在上个季度又购买了 3,519,187 股。北方信托公司在第四季度将其在艾伯维的持股增加了 11.8%。北方信托公司目前拥有 21,824,626 股该公司的股票，价值 3,878,236,000 美元，此前在此期间又收购了 2,299,645 股。德意志银行在第四季度将其在艾伯维的持股增加了 27.4%。德意志银行目前拥有 9,769,102 股该公司的股票，价值 1,735,969,000 美元，此前在上个季度又收购了 2,102,273 股。最后，瑞银资产管理公司（UBS AM）作为瑞银资产管理美洲公司的一个独立业务单位，在第四季度将其在艾伯维的持股增加了 18.5%。瑞银资产管理公司目前拥有 12,058,706 股该公司的股票，价值 2,142,832,000 美元，此前在上个季度又购买了 1,882,780 股。机构投资者目前持有该公司 70.23% 的股票。</p>
<h2>艾伯维股价下跌 1.1%</h2>
<p>周四，艾伯维的开盘价为 196.37 美元。该公司的债务与股本比率为 44.14，速动比率为 0.64，流动比率为 0.74。该股票的 50 日移动平均价格为 188.86 美元，200 日移动平均价格为 190.65 美元。艾伯维公司的股价一年最低为 163.81 美元，一年最高为 218.66 美元。该股票的市值为 3469 亿美元，市盈率为 93.51，市盈增长比率为 1.27，贝塔值为 0.50。</p>
<ul>
<li>三家生物科技巨头受益于美国销售和政策变化</li>
</ul>
<p>艾伯维（NYSE:ABBV - 获取免费报告）最近于 7 月 31 日发布了其财报。该公司报告本季度每股收益为 2.97 美元，低于市场共识预期的 3.24 美元，差额为 0.27 美元。该公司本季度的收入为 154.2 亿美元，而市场共识预期为 149.3 亿美元。艾伯维的股本回报率为 699.66%，净利润率为 6.45%。与去年同期相比，该公司的季度收入增长了 6.6%。去年同期，该公司每股收益为 2.65 美元。分析师平均预测艾伯维公司今年将发布 12.31 美元的每股收益。</p>
<h2>艾伯维宣布分红</h2>
<p>该公司最近还披露了季度分红，将于 8 月 15 日（星期五）支付。7 月 15 日（星期二）登记在册的投资者将获得 1.64 美元的分红。这代表着每年 6.56 美元的分红和 3.3% 的分红收益率。除息日为 7 月 15 日（星期二）。艾伯维的派息比率目前为 312.38%。</p>
<h2>华尔街分析师预测增长</h2>
<ul>
<li>如果你想购买艾伯维但没有，现在仍然有机会购买</li>
</ul>
<p>几家券商对艾伯维发表了评论。摩根士丹利在 8 月 1 日的研究报告中将艾伯维的目标价从 250.00 美元上调至 255.00 美元，并给予该股票 “超配” 评级。古根海姆在 8 月 1 日的报告中将艾伯维的目标价从 216.00 美元上调至 227.00 美元，并给予该股票 “买入” 评级。花旗集团在 6 月 11 日的报告中将艾伯维的目标价上调至 205.00 美元，并给予该公司 “持有” 评级。华尔街 Zen 在 5 月 22 日的研究报告中将艾伯维的评级从 “强烈买入” 下调至 “买入”。最后，美国银行在 6 月 9 日的研究报告中将艾伯维的目标价上调至 204.00 美元，并给予该公司 “持有” 评级。八位研究分析师对该股票给予了持有评级，十七位给予了买入评级，三位给予了强烈买入评级。根据 MarketBeat 的数据，该公司目前的共识评级为 “适度买入”，平均目标价为 212.81 美元。</p>
<p><strong>获取我们最新的艾伯维股票分析</strong></p>
<h2>关于艾伯维</h2>
<p>（免费报告）</p>
<p>艾伯维公司在全球范围内发现、开发、生产和销售药品。该公司提供 Humira，一种用于自身免疫性和肠道贝赫切特病及脓皮病的注射剂；Skyrizi 用于治疗中度至重度斑块型银屑病、银屑病性疾病和克罗恩病；Rinvoq 用于治疗类风湿性关节炎、银屑病性关节炎、强直性脊柱炎、特应性皮炎、轴性脊柱关节炎、溃疡性结肠炎和克罗恩病；Imbruvica 用于治疗成人血癌患者；Epkinly 用于治疗淋巴瘤；Elahere 用于治疗癌症；Venclexta/Venclyxto 用于治疗血癌。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们更看好的股票超过艾伯维</li>
<li>如何计算股票利润</li>
<li>买入低点？这些收益未达预期的股票提供长期上涨空间</li>
<li>投资旅游股票的好处</li>
<li>RSI 股票在第二季度暴涨 22%——PENN 会跟上这种势头吗？</li>
<li>电动车股票及如何从中获利</li>
<li>DigitalOcean 的专注如何推动爆炸性增长</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1000 美元在艾伯维吗？</h2>
<p>在考虑艾伯维之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而艾伯维并不在名单上。</p>
<p>虽然艾伯维目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

艾伯维

<p>马里兰州退休与养老金系统在第一季度将其在艾伯维（AbbVie Inc.，NYSE:ABBV）的持股减少了 13.2%，目前持有 82,955 股，价值 1,738 万美元。其他对冲基金，包括 GAMMA Investing LLC 和高盛，显著增加了他们的持股。艾伯维报告第二季度每股收益为 2.97 美元，低于预期，但收入增长至 154.2 亿美元。该公司宣布季度股息为 1.64 美元，收益率为 3.3%。分析师的评级不一，目标价格范围在 204 美元至 255 美元之间</p>

<p>Maryland State Retirement &amp; Pension System lessened its stake in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 13.2% in the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 82,955 shares of the company's stock after selling 12,656 shares during the period. Maryland State Retirement &amp; Pension System's holdings in AbbVie were worth $17,381,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>马里兰州退休与养老金系统在第一季度减少了对艾伯维公司（NYSE:ABBV - 免费报告）13.2% 的持股，具体信息见其最近向 SEC 提交的 13F 表格。该基金在此期间出售了 12,656 股后，持有 82,955 股该公司的股票。根据其最近的 SEC 文件，马里兰州退休与养老金系统在艾伯维的持股价值为 17,381,000 美元。</p>
</div><ul>
<li>AbbVie Stock Eyes Breakout as Pipeline and Profits Grow</li>
</ul>
<div class="lb-trans"><ul>
<li>艾伯维股票关注突破，管道和利润增长</li>
</ul>
</div><p>Other hedge funds have also added to or reduced their stakes in the company. GAMMA Investing LLC lifted its holdings in AbbVie by 25,841.6% during the first quarter. GAMMA Investing LLC now owns 10,234,737 shares of the company's stock valued at $2,144,382,000 after purchasing an additional 10,195,284 shares during the last quarter. Goldman Sachs Group Inc. grew its stake in AbbVie by 31.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 14,646,908 shares of the company's stock valued at $3,068,820,000 after buying an additional 3,519,187 shares in the last quarter. Northern Trust Corp raised its holdings in AbbVie by 11.8% during the 4th quarter. Northern Trust Corp now owns 21,824,626 shares of the company's stock valued at $3,878,236,000 after acquiring an additional 2,299,645 shares during the period. Deutsche Bank AG lifted its position in shares of AbbVie by 27.4% during the fourth quarter. Deutsche Bank AG now owns 9,769,102 shares of the company's stock worth $1,735,969,000 after acquiring an additional 2,102,273 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of AbbVie by 18.5% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 12,058,706 shares of the company's stock valued at $2,142,832,000 after purchasing an additional 1,882,780 shares in the last quarter. Institutional investors own 70.23% of the company's stock.</p>
<div class="lb-trans"><p>其他对冲基金也对该公司的持股进行了增减。GAMMA Investing LLC 在第一季度将其在艾伯维的持股增加了 25,841.6%。GAMMA Investing LLC 目前拥有 10,234,737 股该公司的股票，价值 2,144,382,000 美元，此前在上个季度又购买了 10,195,284 股。高盛集团在第一季度将其在艾伯维的持股增加了 31.6%。高盛集团目前拥有 14,646,908 股该公司的股票，价值 3,068,820,000 美元，此前在上个季度又购买了 3,519,187 股。北方信托公司在第四季度将其在艾伯维的持股增加了 11.8%。北方信托公司目前拥有 21,824,626 股该公司的股票，价值 3,878,236,000 美元，此前在此期间又收购了 2,299,645 股。德意志银行在第四季度将其在艾伯维的持股增加了 27.4%。德意志银行目前拥有 9,769,102 股该公司的股票，价值 1,735,969,000 美元，此前在上个季度又收购了 2,102,273 股。最后，瑞银资产管理公司（UBS AM）作为瑞银资产管理美洲公司的一个独立业务单位，在第四季度将其在艾伯维的持股增加了 18.5%。瑞银资产管理公司目前拥有 12,058,706 股该公司的股票，价值 2,142,832,000 美元，此前在上个季度又购买了 1,882,780 股。机构投资者目前持有该公司 70.23% 的股票。</p>
</div><h2>AbbVie Trading Down 1.1%</h2>
<div class="lb-trans"><h2>艾伯维股价下跌 1.1%</h2>
</div><p>ABBV opened at $196.37 on Thursday. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.64 and a current ratio of 0.74. The stock's 50 day moving average price is $188.86 and its 200-day moving average price is $190.65. AbbVie Inc. has a one year low of $163.81 and a one year high of $218.66. The stock has a market cap of $346.90 billion, a price-to-earnings ratio of 93.51, a P/E/G ratio of 1.27 and a beta of 0.50.</p>
<div class="lb-trans"><p>周四，艾伯维的开盘价为 196.37 美元。该公司的债务与股本比率为 44.14，速动比率为 0.64，流动比率为 0.74。该股票的 50 日移动平均价格为 188.86 美元，200 日移动平均价格为 190.65 美元。艾伯维公司的股价一年最低为 163.81 美元，一年最高为 218.66 美元。该股票的市值为 3469 亿美元，市盈率为 93.51，市盈增长比率为 1.27，贝塔值为 0.50。</p>
</div><ul>
<li>3 Biotech Giants Gaining From U.S. Sales and Policy Shifts</li>
</ul>
<div class="lb-trans"><ul>
<li>三家生物科技巨头受益于美国销售和政策变化</li>
</ul>
</div><p>AbbVie (NYSE:ABBV - Get Free Report) last released its earnings results on Thursday, July 31st. The company reported $2.97 earnings per share for the quarter, missing the consensus estimate of $3.24 by ($0.27). The business had revenue of $15.42 billion for the quarter, compared to the consensus estimate of $14.93 billion. AbbVie had a return on equity of 699.66% and a net margin of 6.45%. The firm's revenue for the quarter was up 6.6% compared to the same quarter last year. During the same quarter last year, the business posted $2.65 earnings per share. On average, equities analysts forecast that AbbVie Inc. will post 12.31 EPS for the current year.</p>
<div class="lb-trans"><p>艾伯维（NYSE:ABBV - 获取免费报告）最近于 7 月 31 日发布了其财报。该公司报告本季度每股收益为 2.97 美元，低于市场共识预期的 3.24 美元，差额为 0.27 美元。该公司本季度的收入为 154.2 亿美元，而市场共识预期为 149.3 亿美元。艾伯维的股本回报率为 699.66%，净利润率为 6.45%。与去年同期相比，该公司的季度收入增长了 6.6%。去年同期，该公司每股收益为 2.65 美元。分析师平均预测艾伯维公司今年将发布 12.31 美元的每股收益。</p>
</div><h2>AbbVie Announces Dividend</h2>
<div class="lb-trans"><h2>艾伯维宣布分红</h2>
</div><p>The company also recently disclosed a quarterly dividend, which will be paid on Friday, August 15th. Investors of record on Tuesday, July 15th will be issued a $1.64 dividend. This represents a $6.56 annualized dividend and a dividend yield of 3.3%. The ex-dividend date is Tuesday, July 15th. AbbVie's payout ratio is presently 312.38%.</p>
<div class="lb-trans"><p>该公司最近还披露了季度分红，将于 8 月 15 日（星期五）支付。7 月 15 日（星期二）登记在册的投资者将获得 1.64 美元的分红。这代表着每年 6.56 美元的分红和 3.3% 的分红收益率。除息日为 7 月 15 日（星期二）。艾伯维的派息比率目前为 312.38%。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><ul>
<li>If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy</li>
</ul>
<div class="lb-trans"><ul>
<li>如果你想购买艾伯维但没有，现在仍然有机会购买</li>
</ul>
</div><p>Several brokerages have commented on ABBV. Morgan Stanley raised their target price on AbbVie from $250.00 to $255.00 and gave the stock an &#34;overweight&#34; rating in a research note on Friday, August 1st. Guggenheim upped their target price on shares of AbbVie from $216.00 to $227.00 and gave the stock a &#34;buy&#34; rating in a report on Friday, August 1st. Citigroup raised their price target on shares of AbbVie to $205.00 and gave the company a &#34;hold&#34; rating in a report on Wednesday, June 11th. Wall Street Zen downgraded AbbVie from a &#34;strong-buy&#34; rating to a &#34;buy&#34; rating in a research report on Thursday, May 22nd. Finally, Bank of America lifted their price objective on AbbVie to $204.00 and gave the company a &#34;hold&#34; rating in a research note on Monday, June 9th. Eight research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $212.81.</p>
<div class="lb-trans"><p>几家券商对艾伯维发表了评论。摩根士丹利在 8 月 1 日的研究报告中将艾伯维的目标价从 250.00 美元上调至 255.00 美元，并给予该股票 “超配” 评级。古根海姆在 8 月 1 日的报告中将艾伯维的目标价从 216.00 美元上调至 227.00 美元，并给予该股票 “买入” 评级。花旗集团在 6 月 11 日的报告中将艾伯维的目标价上调至 205.00 美元，并给予该公司 “持有” 评级。华尔街 Zen 在 5 月 22 日的研究报告中将艾伯维的评级从 “强烈买入” 下调至 “买入”。最后，美国银行在 6 月 9 日的研究报告中将艾伯维的目标价上调至 204.00 美元，并给予该公司 “持有” 评级。八位研究分析师对该股票给予了持有评级，十七位给予了买入评级，三位给予了强烈买入评级。根据 MarketBeat 的数据，该公司目前的共识评级为 “适度买入”，平均目标价为 212.81 美元。</p>
</div><p><strong>Get Our Latest Stock Analysis on ABBV</strong></p>
<div class="lb-trans"><p><strong>获取我们最新的艾伯维股票分析</strong></p>
</div><h2>About AbbVie</h2>
<div class="lb-trans"><h2>关于艾伯维</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.</p>
<div class="lb-trans"><p>艾伯维公司在全球范围内发现、开发、生产和销售药品。该公司提供 Humira，一种用于自身免疫性和肠道贝赫切特病及脓皮病的注射剂；Skyrizi 用于治疗中度至重度斑块型银屑病、银屑病性疾病和克罗恩病；Rinvoq 用于治疗类风湿性关节炎、银屑病性关节炎、强直性脊柱炎、特应性皮炎、轴性脊柱关节炎、溃疡性结肠炎和克罗恩病；Imbruvica 用于治疗成人血癌患者；Epkinly 用于治疗淋巴瘤；Elahere 用于治疗癌症；Venclexta/Venclyxto 用于治疗血癌。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than AbbVie</li>
<li>How to Calculate Stock Profit</li>
<li>Buy the Dip? These Earnings Misses Offer Long-Term Upside</li>
<li>Investing in Travel Stocks Benefits</li>
<li>RSI Stock Soars 22% On Q2 Blowout—Will PENN Match the Momentum?</li>
<li>EV Stocks and How to Profit from Them</li>
<li>How DigitalOcean's Focus Is Fueling Explosive Growth</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过艾伯维</li>
<li>如何计算股票利润</li>
<li>买入低点？这些收益未达预期的股票提供长期上涨空间</li>
<li>投资旅游股票的好处</li>
<li>RSI 股票在第二季度暴涨 22%——PENN 会跟上这种势头吗？</li>
<li>电动车股票及如何从中获利</li>
<li>DigitalOcean 的专注如何推动爆炸性增长</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=ABBV"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in AbbVie Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在艾伯维吗？</h2>
</div><p>Before you consider AbbVie, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑艾伯维之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而艾伯维并不在名单上。</p>
</div><p>While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然艾伯维目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

马里兰州退休与养老金系统减少了其在艾伯维公司（NYSE:ABBV）的持股